Franklin Resources’s Verve Therapeutics VERV Stock Holding History

Franklin Resources’s Portfolio VERV Stock Details VERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-47,783	Closed	-$537K	–	3257
2025 Q2	$537K	Buy	47,783 +13,662	+40%	+$77.9K	﹤0.01%	2291
2025 Q1	$156K	Buy	34,121 +47	+0.1%	+$315	﹤0.01%	2749
2024 Q4	$192K	Sell	34,074 -81	-0.2%	-$457	﹤0.01%	2656
2024 Q3	$172K	Buy	34,155 +5,914	+21%	+$34.4K	﹤0.01%	2668
2024 Q2	$138K	Buy	28,241 +3,319	+13%	+$20.9K	﹤0.01%	2631
2024 Q1	$331K	Buy	24,922 +12	+0%	+$159	﹤0.01%	2429
2023 Q4	$347K	Buy	+24,910	New	+$309K	﹤0.01%	2107

Other funds holding VERV

GCM

Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Franklin Resources's VERV Position: Q3 2025 in Review

Franklin Resources sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 47,783 shares — an estimated $537K sold.

Franklin Resources first reported a position in VERV in Q4 2023 and held it in 7 quarters. The position peaked at $537K in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

Franklin Resources reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
Franklin Resources sold 47,783 Verve Therapeutics shares in Q3 2025, an estimated $537K.
Franklin Resources first reported a position in Verve Therapeutics in Q4 2023 and held it in 7 quarters.
Franklin Resources's Verve Therapeutics position peaked at $537K in Q2 2025.
6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Franklin Resources's 13F filing for Q3 2025, filed 13 Nov 2025.